About ImmunoGen (NASDAQ:IMGN)
ImmunoGen, Inc., a clinical-stage biotechnology company, focuses on developing antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm, as well as coltuximab ravtansine, a CD19-targeting ADC, which is in Phase II trial for DLBCL. ImmunoGen, Inc. has collaborations with Roche; Bayer HealthCare AG; Sanofi; Biotest AG; Novartis Institutes for BioMedical Research, Inc.; Eli Lilly and Company; Amgen; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Jazz Pharmaceuticals plc; and Debiopharm International SA. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:IMGN
CUSIP45253H10
Phone781-895-0600
Debt
Debt-to-Equity Ratio-0.11%
Current Ratio4.95%
Quick Ratio4.94%
Price-To-Earnings
Trailing P/E Ratio-13.69
Forward P/E Ratio-9.42
P/E GrowthN/A
Sales & Book Value
Annual Sales$115.45 million
Price / Sales11.82
Cash FlowN/A
Price / CashN/A
Book Value($0.14) per share
Price / Book-73.36
Profitability
EPS (Most Recent Fiscal Year)($0.75)
Net Income$-96,010,000.00
Net Margins-83.03%
Return on EquityN/A
Return on Assets-33.80%
Miscellaneous
Employees293
Outstanding Shares132,850,000
ImmunoGen (NASDAQ:IMGN) Frequently Asked Questions
What is ImmunoGen's stock symbol?
ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."
How were ImmunoGen's earnings last quarter?
ImmunoGen (NASDAQ:IMGN) announced its quarterly earnings data on Friday, February, 9th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.07) by $0.03. The biotechnology company had revenue of $39.40 million for the quarter, compared to analyst estimates of $39.62 million. ImmunoGen's revenue for the quarter was up 185.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.39) EPS. View ImmunoGen's Earnings History.
What price target have analysts set for IMGN?
8 equities research analysts have issued 12-month price objectives for ImmunoGen's shares. Their predictions range from $5.00 to $18.00. On average, they expect ImmunoGen's stock price to reach $11.50 in the next twelve months. View Analyst Ratings for ImmunoGen.
What are Wall Street analysts saying about ImmunoGen stock?
Here are some recent quotes from research analysts about ImmunoGen stock:
- 1. According to Zacks Investment Research, "ImmunoGen is heavily dependent on its lead ovarian cancer candidate, mirvetuximab soravtansine. Hence, any kind of development or a regulatory setback could hamper the stock. The ovarian cancer space being competitive is also a matter of concern for the company. On the flip side, the company has made a significant progress with mirvetuximab soravtansine. Successful development and subsequent approval of the candidate will be a huge boost to the company as the ovarian cancer market has immense potential. The company has collaborations with big healthcare companies which not only validate its technology but also provides it with funds in the form of milestone and royalty payments. However, the company’s high dependence on its partnerships for revenue is concerning. The company’s shares have outperformed the broader industry in a year's time. Estimates have been stable lately ahead of the company’s Q1 earnings release." (4/16/2018)
- 2. Cantor Fitzgerald analysts commented, "FORWARD Progress. The nearest term commercial opportunity for IMGN is the FORWARD I trial, which is exploring mirvetuximab soravtansine (mirva") as a single agent in 3rd line ovarian cancer in women who express high levels of the FRa receptor. This trial could read out in 2019 pending completion of enrollment in 2018." (11/3/2017)
- 3. Cowen Inc analysts commented, "IMGN announced a collaboration agreement with Jazz for the development and." (8/29/2017)
Are investors shorting ImmunoGen?
ImmunoGen saw a drop in short interest in the month of March. As of March 29th, there was short interest totalling 11,049,179 shares, a drop of 19.0% from the March 15th total of 13,635,294 shares. Based on an average daily trading volume, of 4,627,482 shares, the short-interest ratio is presently 2.4 days. Currently, 8.4% of the company's stock are short sold.
Who are some of ImmunoGen's key competitors?
Some companies that are related to ImmunoGen include Ultragenyx Pharmaceutical (RARE), Emergent BioSolutions (EBS), Amicus Therapeutics (FOLD), Ascendis Pharma (ASND), Evotec A.G. (EVTCY), Clovis Oncology (CLVS), Ironwood Pharmaceuticals (IRWD), Supernus Pharmaceuticals (SUPN), Acadia Pharmaceuticals (ACAD), Akorn (AKRX), Puma Biotechnology (PBYI), Horizon Pharma (HZNP), Heron Therapeutics (HRTX), Global Blood Therapeutics (GBT), Portola Pharmaceuticals (PTLA), AnaptysBio (ANAB), Medicines (MDCO) and Motif (MTFB).
Who are ImmunoGen's key executives?
ImmunoGen's management team includes the folowing people:
- Mr. Mark J. Enyedy, Pres, CEO & Director (Age 54)
- Mr. David B. Johnston, Exec. VP, CFO & Principal Accounting Officer (Age 63)
- Dr. Richard J. Gregory, Exec. VP & Chief Scientific Officer (Age 60)
- Dr. Anna Berkenblit, VP & Chief Medical Officer (Age 48)
- Ms. Carol Hausner, Exec. Director of Investor Relations & Corp. Communications
Has ImmunoGen been receiving favorable news coverage?
Media headlines about IMGN stock have been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. ImmunoGen earned a news impact score of 0.16 on Accern's scale. They also gave media coverage about the biotechnology company an impact score of 47.19 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
How do I buy shares of ImmunoGen?
Shares of IMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ImmunoGen's stock price today?
One share of IMGN stock can currently be purchased for approximately $10.27.
How big of a company is ImmunoGen?
ImmunoGen has a market capitalization of $1.36 billion and generates $115.45 million in revenue each year. The biotechnology company earns $-96,010,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis. ImmunoGen employs 293 workers across the globe.
How can I contact ImmunoGen?
ImmunoGen's mailing address is 830 WINTER ST, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 781-895-0600 or via email at [email protected]
MarketBeat Community Rating for ImmunoGen (IMGN)
MarketBeat's community ratings are surveys of what our community members think about ImmunoGen and other stocks. Vote "Outperform" if you believe IMGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
ImmunoGen (NASDAQ:IMGN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
8 Wall Street analysts have issued ratings and price targets for ImmunoGen in the last 12 months. Their average twelve-month price target is $11.50, suggesting that the stock has a possible upside of 11.98%. The high price target for IMGN is $18.00 and the low price target for IMGN is $5.00. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.75 | 2.75 | 2.50 | 2.50 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $11.50 | $11.50 | $8.05 | $8.05 |
| Price Target Upside: | 11.98% upside | 6.66% downside | 64.96% upside | 21.60% upside |
ImmunoGen (NASDAQ:IMGN) Consensus Price Target History
ImmunoGen (NASDAQ:IMGN) Analyst Ratings History
Show:
(Data available from 4/22/2016 forward)
ImmunoGen (NASDAQ:IMGN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
ImmunoGen (NASDAQ IMGN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 6.51%
Institutional Ownership Percentage: 78.24%
ImmunoGen (NASDAQ IMGN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/16/2018 | Daniel M Junius | Director | Sell | 25,000 | $12.02 | $300,500.00 | 209,987 |  |
| 3/15/2018 | David Brannon Johnston | CFO | Sell | 10,000 | $11.53 | $115,300.00 | 190,690 | |
| 2/21/2018 | David Brannon Johnston | CFO | Sell | 21,060 | $10.87 | $228,922.20 | 180,690 | |
| 2/21/2018 | Mark J Enyedy | CEO | Sell | 67,717 | $10.87 | $736,083.79 | 532,383 | |
| 2/21/2018 | Richard J Gregory | VP | Sell | 34,486 | $10.88 | $375,207.68 | 239,094 | |
| 2/20/2018 | Daniel M Junius | Director | Sell | 25,000 | $11.68 | $292,000.00 | 196,700 | |
| 2/13/2018 | Daniel M Junius | Director | Sell | 46,667 | $10.01 | $467,136.67 | 243,367 | |
| 1/8/2018 | Richard J Gregory | VP | Sell | 2,904 | $6.64 | $19,282.56 | 273,577 | |
| 9/15/2017 | Craig Barrows | VP | Sell | 37,050 | $6.81 | $252,310.50 | 51,100 | |
| 9/13/2017 | Craig Barrows | VP | Sell | 14,600 | $6.95 | $101,470.00 | 51,100 | |
| 12/15/2016 | Mark Alan Goldberg | Director | Buy | 20,000 | $1.80 | $36,000.00 | 23,800 | |
| 11/8/2016 | Mark J Enyedy | CEO | Buy | 25,000 | $1.83 | $45,750.00 | 100,100 | |
| 11/2/2016 | Craig Barrows | Insider | Buy | 10,000 | $1.71 | $17,100.00 | 31,100 | |
| 11/2/2016 | Richard J Gregory | VP | Buy | 16,600 | $1.78 | $29,548.00 | 39,231 | |
| 2/1/2016 | John Lambert | EVP | Sell | 3,889 | $8.22 | $31,967.58 | 106,857 | |
| 1/8/2016 | Richard J Gregory | VP | Sell | 2,369 | $11.10 | $26,295.90 | 22,631 | |
| 1/4/2016 | Daniel M. Junius | CEO | Sell | 5,416 | $13.17 | $71,328.72 | 169,615 | |
| 1/4/2016 | John Lambert | EVP | Sell | 3,889 | $13.20 | $51,334.80 | 106,857 | |
| 12/1/2015 | Daniel M. Junius | CEO | Sell | 5,416 | $13.11 | $71,003.76 | 170,618 | |
| 12/1/2015 | John Lambert | EVP | Sell | 3,889 | $13.11 | $50,984.79 | 106,857 | |
| 11/27/2015 | Charles Q Morris | VP | Sell | 5,170 | $14.00 | $72,380.00 | 27,090 | |
| 11/17/2015 | Dean J Mitchell | Director | Buy | 10,000 | $12.51 | $125,100.00 | 10,000 | |
| 11/2/2015 | Daniel M. Junius | CEO | Sell | 5,497 | $12.00 | $65,964.00 | 159,812 | |
| 11/2/2015 | John Lambert | EVP | Sell | 3,889 | $11.73 | $45,617.97 | 106,857 | |
| 10/29/2015 | Daniel M. Junius | CEO | Sell | 5,335 | $12.01 | $64,073.35 | 154,115 | |
| 10/1/2015 | John Lambert | EVP | Sell | 3,889 | $9.55 | $37,139.95 | 106,857 | |
| 9/17/2015 | David Brannon Johnston | CFO | Sell | 5,000 | $15.00 | $75,000.00 | | |
| 9/1/2015 | Daniel M. Junius | CEO | Sell | 5,416 | $13.15 | $71,220.40 | 154,115 | |
| 9/1/2015 | John Lambert | EVP | Sell | 3,889 | $13.16 | $51,179.24 | 106,857 | |
| 7/1/2015 | Daniel M Junius | CEO | Sell | 5,416 | $14.34 | $77,665.44 | | |
| 7/1/2015 | John Lambert | EVP | Sell | 3,888 | $14.34 | $55,753.92 | | |
| 6/15/2015 | Nicole Onetto | Director | Sell | 3,211 | $13.86 | $44,504.46 | | |
| 6/1/2015 | John Lambert | EVP | Sell | 15,000 | $11.78 | $176,700.00 | | |
| 5/7/2015 | Daniel M Junius | CEO | Sell | 1,215 | $8.02 | $9,744.30 | | |
| 5/1/2015 | John Lambert | EVP | Sell | 10,000 | $8.32 | $83,200.00 | | |
| 11/28/2014 | Charles Q Morris | VP | Sell | 5,240 | $10.40 | $54,496.00 | | |
| 3/17/2014 | Daniel Junius | CEO | Sell | 15,000 | $16.40 | $246,000.00 | 80,636 | |
| 2/26/2014 | Charles Morris | VP | Sell | 6,936 | $17.35 | $120,339.60 | 37,500 | |
| 2/20/2014 | Charles Morris | VP | Sell | 13,672 | $17.10 | $233,791.20 | 37,500 | |
| 2/18/2014 | Daniel Junius | CEO | Sell | 15,000 | $16.26 | $243,900.00 | 80,636 | |
| 2/3/2014 | John Lambert | EVP | Sell | 4,375 | $14.90 | $65,187.50 | 106,857 | |
| 1/22/2014 | Charles Morris | VP | Sell | 7,138 | $17.00 | $121,346.00 | 37,500 | |
| 1/10/2014 | Theresa Wingrove | VP | Sell | 6,250 | $15.04 | $94,000.00 | | |
| 1/2/2014 | John Lambert | EVP | Sell | 4,375 | $14.53 | $63,568.75 | 106,857 | |
| 12/10/2013 | Daniel Junius | CEO | Sell | 15,000 | $15.11 | $226,650.00 | 73,336 | |
| 12/2/2013 | John Lambert | EVP | Sell | 4,375 | $14.70 | $64,312.50 | 106,857 | |
| 11/26/2013 | Charles Morris | VP | Sell | 12,500 | $13.75 | $171,875.00 | 37,500 | |
| 11/1/2013 | John Lambert | EVP | Sell | 4,375 | $16.41 | $71,793.75 | | |
| 9/10/2013 | Gregory D Perry | CFO | Sell | 18,337 | $17.82 | $326,765.34 | | |
| 9/3/2013 | Daniel Junius | CEO | Sell | 16,667 | $16.43 | $273,838.81 | 73,336 | |
| 9/3/2013 | John Lambert | EVP | Sell | 4,375 | $16.45 | $71,968.75 | 106,857 | |
| 8/1/2013 | Daniel M Junius | CEO | Sell | 16,667 | $19.21 | $320,173.07 | | |
| 8/1/2013 | John Lambert | EVP | Sell | 4,375 | $19.21 | $84,043.75 | | |
| 7/11/2013 | James J O'leary | VP | Sell | 35,000 | $19.02 | $665,700.00 | | |
| 7/3/2013 | Daniel M Junius | CEO | Sell | 16,667 | $17.31 | $288,505.77 | | |
| 7/1/2013 | John Lambert | EVP | Sell | 4,375 | $16.80 | $73,500.00 | | |
| 6/3/2013 | John Lambert | EVP | Sell | 11,250 | $17.20 | $193,500.00 | | |
| 5/24/2013 | James J O'leary | VP | Sell | 28,900 | $18.11 | $523,379.00 | | |
| 5/1/2013 | John Lambert | EVP | Sell | 11,250 | $15.56 | $175,050.00 | | |
| 4/11/2013 | James J O'leary | VP | Sell | 31,100 | $17.37 | $540,207.00 | | |
| 11/8/2012 | Mark Alan Goldberg | Director | Buy | 3,000 | $11.27 | $33,810.00 | | |
(Data available from 1/1/2013 forward)
ImmunoGen (NASDAQ IMGN) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | $15.29 Million in Sales Expected for ImmunoGen (IMGN) This Quarter
www.americanbankingnews.com - April 22 at 4:56 AM |
| ImmunoGen (IMGN) Given a $5.00 Price Target by Royal Bank of Canada Analysts
www.americanbankingnews.com - April 20 at 2:25 PM |
 | ImmunoGen Announces Conference Call to Discuss Its First Quarter 2018 Operating Results
finance.yahoo.com - April 20 at 10:03 AM |
| ImmunoGen (IMGN) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - April 20 at 1:26 AM |
| ImmunoGen (IMGN) Expected to Post Earnings of -$0.27 Per Share
www.americanbankingnews.com - April 20 at 1:26 AM |
| Stock Traders Buy High Volume of ImmunoGen Put Options (IMGN)
www.americanbankingnews.com - April 19 at 8:32 AM |
 | Are Options Traders Betting on a Big Move in ImmunoGen (IMGN) Stock? April 18, 2018
www.zacks.com - April 18 at 10:06 AM |
| Are Options Traders Betting on a Big Move in ImmunoGen (IMGN) Stock?
finance.yahoo.com - April 18 at 10:06 AM |
| Brokers Set Expectations for ImmunoGen's Q1 2018 Earnings (IMGN)
www.americanbankingnews.com - April 18 at 7:54 AM |
| ImmunoGen (IMGN) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 16 at 1:21 PM |
| Canaccord Genuity Analysts Give ImmunoGen (IMGN) a $8.00 Price Target
www.americanbankingnews.com - April 14 at 4:12 PM |
| ImmunoGen to Post FY2018 Earnings of ($1.08) Per Share, Cantor Fitzgerald Forecasts (IMGN)
www.americanbankingnews.com - April 13 at 9:22 AM |
| ImmunoGen (IMGN) Short Interest Down 19.0% in March
www.americanbankingnews.com - April 13 at 3:43 AM |
| ImmunoGen Expected to Post FY2019 Earnings of ($0.87) Per Share (IMGN)
www.americanbankingnews.com - April 12 at 8:03 AM |
| ImmunoGen (IMGN) Given Buy Rating at HC Wainwright
www.americanbankingnews.com - April 10 at 8:37 AM |
| ValuEngine Downgrades ImmunoGen (IMGN) to Sell
www.americanbankingnews.com - April 10 at 8:27 AM |
| ImmunoGen (IMGN) Rating Reiterated by Cantor Fitzgerald
www.americanbankingnews.com - April 8 at 11:17 AM |
| ImmunoGen (IMGN) Raised to Hold at ValuEngine
www.americanbankingnews.com - April 5 at 1:11 PM |
| ImmunoGen (IMGN) Expected to Announce Quarterly Sales of $15.29 Million
www.americanbankingnews.com - April 5 at 5:53 AM |
| ImmunoGen, Inc. (IMGN) Expected to Announce Earnings of -$0.27 Per Share
www.americanbankingnews.com - April 3 at 1:14 AM |
| ImmunoGen (IMGN) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - April 2 at 7:31 PM |
| Fast Pipeline Progress Pushes ImmunoGen Above 150% in a Year
finance.yahoo.com - April 2 at 4:07 PM |
| ImmunoGen (IMGN) Cut to "Buy" at BidaskClub
www.americanbankingnews.com - March 30 at 11:06 AM |
| What Knocked ImmunoGen, Inc. Down 15% on Tuesday?
finance.yahoo.com - March 28 at 3:58 PM |
| ImmunoGen (IMGN) Downgraded by ValuEngine to Sell
www.americanbankingnews.com - March 28 at 11:55 AM |
| ImmunoGen (IMGN) Given "Outperform" Rating at Leerink Swann
www.americanbankingnews.com - March 28 at 10:26 AM |
| ImmunoGen, Inc. (IMGN) to Post FY2020 Earnings of ($1.26) Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - March 28 at 7:11 AM |
| ImmunoGen, Inc. (IMGN) Expected to Earn Q1 2019 Earnings of ($0.28) Per Share
www.americanbankingnews.com - March 28 at 6:54 AM |
| Brokers Offer Predictions for ImmunoGen, Inc.'s Q1 2018 Earnings (IMGN)
www.americanbankingnews.com - March 28 at 6:38 AM |
| ImmunoGen (IMGN) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - March 27 at 3:28 PM |
| ImmunoGen (IMGN) Jumps: Stock Rises 7%
finance.yahoo.com - March 27 at 10:11 AM |
| HC Wainwright Initiates Coverage on ImmunoGen (IMGN)
www.americanbankingnews.com - March 26 at 10:58 AM |
 | ImmunoGen's mirvetuximab soravtansine shows positive effect in Phase 1/2 ovarian cancer study; shares up 12 ...
seekingalpha.com - March 26 at 10:49 AM |
| Cantor Fitzgerald Analysts Give ImmunoGen (IMGN) a $5.00 Price Target
www.americanbankingnews.com - March 26 at 8:37 AM |
| HC Wainwright Analysts Give ImmunoGen (IMGN) a $18.00 Price Target
www.americanbankingnews.com - March 26 at 8:36 AM |
| ImmunoGen, Inc. (IMGN) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - March 26 at 1:34 AM |
 | ImmunoGen Presents Data from FORWARD II Assessment of Mirvetuximab Soravtansine in Combination with ...
www.businesswire.com - March 25 at 9:34 AM |
| Is the Options Market Predicting a Spike in ImmunoGen (IMGN) Stock? March 23, 2018
www.zacks.com - March 24 at 4:28 PM |
| Is the Options Market Predicting a Spike in ImmunoGen (IMGN) Stock?
finance.yahoo.com - March 23 at 9:36 AM |
| ImmunoGen (IMGN) PT Raised to $16.00 at Royal Bank of Canada
www.americanbankingnews.com - March 21 at 1:57 PM |
| ImmunoGen (IMGN) Lifted to Hold at ValuEngine
www.americanbankingnews.com - March 21 at 12:48 AM |
| Zacks Investment Research Upgrades ImmunoGen (IMGN) to Hold
www.americanbankingnews.com - March 19 at 1:45 PM |
| ImmunoGen (IMGN) Upgraded by ValuEngine to Hold
www.americanbankingnews.com - March 18 at 10:28 PM |
| -$0.27 EPS Expected for ImmunoGen, Inc. (IMGN) This Quarter
www.americanbankingnews.com - March 16 at 11:08 PM |
| Daniel M. Junius Sells 25,000 Shares of ImmunoGen, Inc. (IMGN) Stock
www.americanbankingnews.com - March 16 at 7:52 PM |
| ImmunoGen, Inc. (IMGN) CFO David Brannon Johnston Sells 10,000 Shares
www.americanbankingnews.com - March 16 at 10:19 AM |
 | Jim Cramer Advises His Viewers On Disney, AMD, RH And More
www.benzinga.com - March 15 at 10:51 AM |
| ImmunoGen Announces Presentations at AACR Annual Meeting Highlighting Continued Innovation in ADCs
finance.yahoo.com - March 15 at 10:51 AM |
| Harry Boxer’s six stocks to watch, including two short-sale candidates
finance.yahoo.com - March 14 at 12:41 PM |
 | Commit To Buy ImmunoGen At $8, Earn 31.6% Annualized Using Options - Nasdaq
www.nasdaq.com - March 12 at 4:02 PM |
ImmunoGen (NASDAQ:IMGN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
ImmunoGen (NASDAQ:IMGN) Income Statement, Balance Sheet and Cash Flow Statement
ImmunoGen (NASDAQ IMGN) Stock Chart for Sunday, April, 22, 2018
Loading chart…
